First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2- Breast Cancer.

ABSTRACT: Women with hormone receptor-positive, human epidermal growth factor receptor 2- negative breast cancer-the most common subtype-have new options as palbociclib and similar drugs debut. This article outlines the rationale and evidence for their use.

SUBMITTER: McCain J 

PROVIDER: S-EPMC4517534 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature